Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development
- 13 April 2022
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 14 (19) , 7110-7122
Abstract
This review summarized the current progress on nanobody screening and their applications in protein structure determination, development of therapeutics crossing the blood–brain barrier (BBB), and development of non-injectable or bispecific drugs.Keywords
Funding Information
- National Natural Science Foundation of China (31670738, 31470730)
This publication has 122 references indexed in Scilit:
- Orally fed seeds producing designer IgAs protect weaned piglets against enterotoxigenicEscherichia coliinfectionProceedings of the National Academy of Sciences, 2013
- Nanobody-coupled microbubbles as novel molecular tracerJournal of Controlled Release, 2012
- Dual Beneficial Effect of Interloop Disulfide Bond for Single Domain Antibody FragmentsJournal of Biological Chemistry, 2012
- Engineered Single-Domain Antibodies with High Protease Resistance and Thermal StabilityPLOS ONE, 2011
- Structure of a nanobody-stabilized active state of the β2 adrenoceptorNature, 2011
- Engineering of recombinant crystallization chaperonesCurrent Opinion in Structural Biology, 2009
- Crystal structure of full-length KcsA in its closed conformationProceedings of the National Academy of Sciences, 2009
- Immunological applications of single-domain llama recombinant antibodies isolated from a naïve libraryProtein Engineering, Design and Selection, 2009
- High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled ReceptorScience, 2007
- Contributions of CDR3 to VHH Domain Stability and the Design of Monobody Scaffolds for Naive Antibody LibrariesJournal of Molecular Biology, 2003